LIGAND PHARMACEUTICALS INCORPORATED Adjustments to Additional Paid in Capital, Warrant Issued
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Adjustments to Additional Paid in Capital, Warrant Issued of $200.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2023-02-28
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, warrant issued for the quarter ending 2022-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, warrant issued for the quarter ending 2021-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, warrant issued for the quarter ending 2021-03-31 was $400.00K.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, warrant issued for fiscal 2022 was $200.00K, a 60.00% decline from fiscal 2021.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, warrant issued for fiscal 2021 was $500.00K.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, warrant issued for fiscal 2014 was $11.64M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 1 month | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $200.00K 10-K · filed 2023-02-28 | ||
| 2022-09-30 | $200.00K 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $500.00K 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $500.00K 10-Q · filed 2021-11-09 | |||
| 2021-03-31 | $400.00K 10-Q · filed 2021-08-03 | $400.00K 10-Q · filed 2021-05-06 | ||
| 2014-12-31 | $11.64M 10-K · filed 2017-02-28 | |||
| 2014-08-31 | $11.60M 10-K · filed 2021-02-24 |